Oracle launches safety-reporting platform in China for growing clinical trial market

By Flora Southey contact

- Last updated on GMT

(Image: Getty/aiqingwang)
(Image: Getty/aiqingwang)

Related tags: Clinical trial

Oracle Health Sciences has launched its safety-reporting management software in China to monitor adverse events as the country’s clinical trials industry continues to grow.

In collaboration with China-based clinical services provider dMed Biopharmaceuticals, Oracle will sell its Argus pharmacovigilance system to clinical research organisations (CROs) and drug makers looking to market products both within China and abroad.

“Safety is about collecting adverse events that get reported about medical products,” ​Oracle Health Science’s director of safety analytics Michael Braun-Bogos told us.

“It is very difficult to track, which has led to pharmaceutical companies moving to commercial safety software where the vendor – like Oracle – does all that work to maintain compliance within all relevant countries,” ​he added.

dMed said the collaboration will help its clients optimise global compliance and risk management.

“The Oracle Argus Safety system enables our Pharmacovigilance experts to provide comprehensive case management and safety reporting services,” ​said dMed’s CEO Lingshi Tan.

Increased demand

China has become increasingly interested in aligning its safety regulations​ with the rest of the world, as shown by its recent admission to the International Council for Harmonisation (ICH), which reinforces its need for Oracle’s safety-reporting software, said Braun-Bogos.

According to Braun-Bogos, China’s admission​ to the ICH is “exciting news, because that means they’re committed to starting to harmonise their rules to be aligned with Japan, Europe, Canada and the US, which are also in the ICH.”

He also said as the number of Chinese firms running trials and marketing products across Asia, Europe and the Americas increase, so does the need to comply with international regulators.

“These firms have the issue that they have to be compliant with all the different regulations in each country for safety reporting,” ​he told us.

The US Food and Drug Administration (FDA) recently launched a new online tool​ to enable users to search the FDA Adverse Event Reporting System (FAERS), and the European Medicines Agency’s (EMA) updated EudraVigilance​ is set to go live November 22, 2017.

Related news

Show more

Related products

show more

Stability Testing As a Quality Control Measure

Stability Testing As a Quality Control Measure

Frontage Laboratories | 19-Jun-2019 | Technical / White Paper

Stability testing is, in essence, a quality control process and is there¬fore a vital component of every phase of clinical development for both large and...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars